CG Oncology, Inc. (CGON) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The company has no approved products and relies on equity financing and collaboration revenue. A significant operational change occurred in July 2025 with the acquisition of Biovire, Inc., a contract manufacturing organization, which is now consolidated into the company's financials.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,083 | $52 |
| Net Loss | $(60,202) | $(34,452) |
| Net Loss Per Share (Basic/Diluted) | $(0.71) | $(0.45) |
| Cash, Cash Equivalents & Marketable Securities | $1,076,242 | $257,068 (Cash only) |
| Working Capital | $1,066,927 | N/A |
| Long-Term Debt | $3,000 | $0 |
| Accumulated Deficit | $(439,178) | $(252,433) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $1.1 million from $52,000. This includes $1.1 million in new "Commercial and development revenue" derived from the consolidated operations of Biovire (fill and finish services), which was not present in the prior year.
- Expense Increase: Operating expenses rose to $67.5 million from $42.3 million.
- R&D Expenses: Increased by $16.3 million to $43.7 million, driven by a $14.5 million rise in external clinical trial costs (CMC costs) and higher personnel costs.
- G&A Expenses: Increased by $6.0 million to $20.8 million due to higher compensation and professional fees.
- Cost of Sales: New line item of $3.0 million related to Biovire operations.
- Capital Raise: The company completed its Jefferies Sales Agreement, selling 6.9 million shares for net proceeds of $391.4 million during the quarter.
- Debt: Assumed $3.0 million in long-term debt (Biovire Note) following the July 2025 acquisition.
Outlook, Risks, and Management Commentary
- Regulatory Status: The company initiated a Biologics License Application (BLA) submission for cretostimogene in Q4 2025 and expects to complete it in Q4 2026. The product holds Fast Track and Breakthrough Therapy designations.
- Liquidity: Management believes current cash and marketable securities ($1.08 billion) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses until regulatory approval and commercialization are achieved.
- Legal Proceedings: A significant lawsuit with ANI Pharmaceuticals regarding royalty obligations was resolved in the company's favor. A jury unanimously rejected ANI's claims for unjust enrichment in July 2025. As of the filing date, post-trial motions are pending, but the company expects no future royalty payments or damages to ANI.
- Risks: Primary risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, the need for substantial additional capital, and reliance on third-party manufacturing (now partially mitigated by the Biovire acquisition).
Investor Verification Checklist
- BLA Timeline: Verify the expected completion date of the Biologics License Application (Q4 2026) and any potential delays.
- Cash Burn Rate: Monitor the quarterly net cash used in operating activities ($56.9 million in Q1) against the $1.08 billion cash balance to assess runway.
- ANI Litigation Status: Confirm the final ruling on pending post-trial motions to ensure no unexpected liabilities arise.
- Biovire Integration: Assess the financial performance and operational integration of the newly acquired Biovire subsidiary.
- Dilution: Track future equity issuances under the Jefferies Sales Agreement or other capital raises required to fund the BLA process.